CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01787552
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:44.394773+00:00
Published At: 2020-04-15T00:00:00+00:00
Record Updated At: 2020-04-15
Results Posted At: 2020-04-15
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Primary Myelofibrosis", "Thrombocytosis", "Essential Thrombocythemia", "Polycythemia Vera", "Myeloproliferative Disorders", "Bone Marrow Diseases", "Hematologic Diseases", "Blood Coagulation Disorders", "Blood Platelet Disorders", "Hemorrhagic Disorders"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-04-15"
protocolSection.identificationModule.nctId: "NCT01787552"
protocolSection.identificationModule.officialTitle: "A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2020-04-15"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.